Categories Earnings, Health Care

Acasti Pharma (ACST): Q3 2020 Earnings Snapshot

— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.

— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.

— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.

— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.

— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.

— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.

— ACST shares gained 0.69% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Trxade (MEDS) is increasing the breadth of product offerings: CEO Suren Ajjarapu

Trxade Health Inc. (NASDAQ: MEDS) is an online pharmaceutical marketplace that provides a platform for independent pharmacies to operate more effectively. The company’s digital platform helps optimize drug procurement and

AMAT Stock: Is now the right time to invest in Applied Materials?

It is estimated that the size of the global chip manufacturing equipment market would nearly double from the current levels to about $142 billion in the next eight years. Applied

Here’s a look at Take-Two Interactive Software’s (TTWO) expectations for the coming year

Shares of Take-Two Interactive Software (NASDAQ: TTWO) were down over 2% on Friday. The stock has dropped 32% year-to-date and 35% over the past 12 months. Earlier this week, the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top